UroGen Pharma Ltd. (URGN) Earning

NASDAQ Currency in USD Disclaimer

$10.82

north_east $0.11 (1.03%)
Day's range
$10.51
Day's range
$10.88

UroGen Pharma Ltd. Analyst EPS Estimates

Quarter Number of Estimates Low Estimate High Estimate Average Estimate
Q1 2024 1 -$0.93 -$0.82 -$0.87
Q2 2024 1 -$0.89 -$0.79 -$0.83
Q3 2024 3 -$0.88 -$0.78 -$0.82
Q4 2024 5 -$0.80 -$0.63 -$0.72
Q1 2025 4 -$0.91 -$0.69 -$0.80
Q2 2025 2 -$0.86 -$0.76 -$0.80
Q3 2025 2 -$0.71 -$0.63 -$0.66
Q4 2025 2 -$0.47 -$0.42 -$0.44
Q1 2026 1 $0.47 $0.53 $0.50
Q2 2026 1 $0.51 $0.58 $0.54
Q3 2026 1 $0.48 $0.55 $0.51
Q4 2026 1 $0.47 $0.54 $0.50
Q1 2027 1 $0.94 $1.06 $0.99
Q2 2027 1 $0.98 $1.11 $1.03
Q3 2027 1 $0.96 $1.08 $1.01
Q4 2027 1 $0.97 $1.10 $1.02
Q1 2028 2 $0.89 $1.01 $0.94
Q2 2028 2 $1.09 $1.24 $1.15
Q3 2028 2 $1.07 $1.21 $1.13
Q4 2028 2 $1.09 $1.23 $1.15

UroGen Pharma Ltd. Earnings Date And Information

UroGen Pharma Ltd. last posted its earnings results on Wednesday, November 6th, 2024. The company reported $-0.55 earnings per share for the quarter, topping analysts' consensus estimates of $-0.84 by $0.29. The company had revenue of 25.20 M for the quarter and had revenue of 82.71 M for the year. UroGen Pharma Ltd. has generated $-4 earnings per share over the last year ($-3.55 diluted earnings per share) and currently has a price-to-earnings ratio of -4.04. UroGen Pharma Ltd. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, March 12th, 2025 based on prior year's report dates.

UroGen Pharma Ltd. Earnings History by Quarter

Date Quarter Consensus Estimate Reported EPS Beat/Miss Revenue Estimate Actual Revenue
11/06/2024 Q3 2024 -$0.84 -$0.55 0.29 $24.20 M $25.20 M
08/13/2024 Q2 2024 -$0.82 -$0.91 -0.09 $23.97 M $21.85 M
05/13/2024 Q1 2024 -$0.93 -$0.97 -0.04 $18.78 M
04/29/2024 Q4 2023 -$0.72 $23.53 M
09/29/2023 Q3 2023 -$0.68 $20.03 M $20.85 M
08/10/2023 Q2 2023 -$1.13 -$1.03 0.1 $20.12 M $21.14 M
05/11/2023 Q1 2023 -$1.39 -$1.30 0.09 $17.19 M
05/01/2023 Q4 2022 -$1.22 $18.09 M
11/10/2022 Q3 2022 -$1.22 -$1.13 0.09 $20.15 M $16.10 M
08/11/2022 Q2 2022 -$1.33 -$1.18 0.15 $17.22 M $16.60 M
05/10/2022 Q1 2022 -$1.36 -$1.25 0.11 $13.56 M
03/21/2022 Q4 2021 -$1.18 -$1.27 -0.09 $16.17 M
11/15/2021 Q3 2021 -$1.26 -$1.35 -0.09 $15.37 M $11.35 M
08/04/2021 Q2 2021 -$1.10 -$1.17 -0.07 $11.76 M $13.03 M
05/13/2021 Q1 2021 -$1.26 -$1.17 0.09 $7.49 M
03/18/2021 Q4 2020 -$1.31 -$1.38 -0.07 $7.97 M
11/09/2020 Q3 2020 -$1.47 -$1.31 0.16 $3.33 M $3.46 M
08/10/2020 Q2 2020 -$1.55 -$1.44 0.11 $396,167 $372,000
05/07/2020 Q1 2020 -$1.61 -$1.79 -0.18 $0
03/02/2020 Q4 2019 -$1.69 -$1.86 -0.17 $0
 

UroGen Pharma Ltd. Earnings: FAQ's

When is UroGen Pharma Ltd.'s earnings date?

UroGen Pharma Ltd. has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, March 12th, 2025 based off last year's report dates.

Did UroGen Pharma Ltd. beat their earnings estimates last quarter?

In the previous quarter, UroGen Pharma Ltd. (:URGN) reported $-0.55 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.84 by $0.29.

How can I listen to UroGen Pharma Ltd.'s earnings conference call?

The conference call for UroGen Pharma Ltd.'s latest earnings report can be listened to online.

How can I read UroGen Pharma Ltd.'s conference call transcript?

The conference call transcript for UroGen Pharma Ltd.'s latest earnings report can be read online.

How much revenue does UroGen Pharma Ltd. generate each year?

UroGen Pharma Ltd. (:URGN) has a recorded annual revenue of $82.71 M.

How much profit does UroGen Pharma Ltd. generate each year?

UroGen Pharma Ltd. (:URGN) has a recorded net income of $82.71 M. UroGen Pharma Ltd. has generated $-3.55 earnings per share over the last four quarters.

What is UroGen Pharma Ltd.'s price-to-earnings ratio?

UroGen Pharma Ltd. (:URGN) has a price-to-earnings ratio of -4.04 and price/earnings-to-growth ratio is -1.02.

Portfolio Sync
Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED